Restart Life Sciences Corp.
NMLSF
$0.05
-$0.02-33.07%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 221.30K | 121.50K | 112.80K | 461.70K | 203.50K |
| Depreciation & Amortization | 300.00 | 300.00 | 300.00 | 300.00 | 400.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 221.60K | 121.90K | 113.10K | 465.50K | 203.90K |
| Operating Income | -221.60K | -121.90K | -113.10K | -465.50K | -203.90K |
| Income Before Tax | -112.80K | -153.20K | -147.10K | -570.50K | 100.00 |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -112.80K | -153.20K | -147.10K | -570.50K | 100.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -112.80K | -153.20K | -147.10K | -570.50K | 100.00 |
| EBIT | -221.60K | -121.90K | -113.10K | -465.50K | -203.90K |
| EBITDA | -221.30K | -121.50K | -112.80K | -465.10K | -203.50K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.02 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 39.29M | 35.89M | 33.59M | 26.73M | 16.67M |
| Average Diluted Shares Outstanding | 39.29M | 35.89M | 33.59M | 26.73M | 18.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |